Tim Guilliams, a 2020 In Vivo Rising Leader, co-founded UK-based Healx Ltd. in 2014 with a mission of developing affordable treatments for rare diseases. In October 2019, the artificial intelligence firm raised $56m in a Series B financing round, led by Atomico, one of Europe’s largest tech-focused venture capital firms. As CEO, Guilliams has grand plans for the future of Healx, as a tech-driven drug developer, not a service provider.
“We started the company in 2014 with a few people around Cambridge University,” Guilliams told In Vivo in a recent...